Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 18,752 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
Interventions: RO5045337; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Santa Monica, California • Houston, Texas • San Antonio, Texas

Conditions: SCLC, Extensive-stage Small Cell Lung Cancer
Interventions: Ifinatamab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
U.S. locations: 6
States / cities: Saint Paul, Minnesota • Bolivar, Missouri • Durham, North Carolina + 3 more

Conditions: B Cell Leukemia
Interventions: Autologous CD19 CAR+ EGFTt + T cells; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 26 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Melanoma
Interventions: Temozolomide, Abraxane, Cisplatin, Interleukin-2, Interferon alpha 2b; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions: Lenalidomide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Multiple Myeloma
Interventions: Bortezomib, Lenalidomide, Dexamethasone, Vorinostat; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Japanese Volunteers
Interventions: Fostamatinib 100mg, Fostamatinib 200mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: FT-2102 (olutasidenib), Azacitidine, Cytarabine; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
Interventions: recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: KarXT; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more

Conditions: Dry Eye Disease
Interventions: OTX-CSI, Placebo Vehicle; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more

Conditions: Acute Myeloid Leukemia
Interventions: TKI258; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease
Interventions: OLX-07010 Active, OLX-07010 Placebo; Drug
Lead sponsor: Oligomerix, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Subject, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
Interventions: Computed Tomography, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Magnetic Resonance Imaging; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 25 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carcinoma, Small Cell
Interventions: GSK2879552; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: St Louis, Missouri • Columbus, Ohio • Nashville, Tennessee

Conditions: Pancreatic Cancer
Interventions: Hydroxychloroquine, Gemcitabine; Drug
Lead sponsor: Amer Zureikat; Other
Eligibility: 19 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Beverly Hills, California • Tampa, Florida • New York, New York

Conditions: Glioblastoma Multiforme
Interventions: Temozolomide, R115777; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: cisplatin, docetaxel, adjuvant therapy; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Nashville, Tennessee

Conditions: Healthy
Interventions: Aerucin 2.0mg/kg, Aerucin 8.0mg/kg, Aerucin 20.0 mg/kg; Biological
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tuberculosis
Interventions: Midazolam, PA-824; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Lung Cancer
Interventions: SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 57
States / cities: Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more

Conditions: Stroke, Vascular Dementia, Memory Deficits
Interventions: Donepezil and self-generated memory training, Donepezil and experimenter-administered memory training; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: imatinib mesylate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants

Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery

Study of Single Doses of IV Aerucin in Healthy Adults

Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Aricept to Improve Functional Tasks in Vascular Dementia

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure